PGx in Cardiology — Antiplatelets, Statins & Warfarin — Hands-on

Connect pharmacogenomics with day to day cardiology decisions. This module focuses on antiplatelets, statins and warfarin, helping you interpret relevant gene–drug pairs, anticipate thrombosis, myopathy and bleeding risk, and write clear, cardiology focused PGx recommendations.

PGx in Cardiology — Antiplatelets Statins and Warfarin

Help Desk · WhatsApp

Session Index

Session 1 — Cardiology PGx Foundations & Pathways Session 2 — Antiplatelets, Thrombosis Risk & PGx Session 3 — Statins, Myopathy Risk & PGx Session 4 — Warfarin, Anticoagulation & PGx Caseboard

Session 1

Fee: Rs 8800

Cardiology PGx Foundations & Pathways

Where pharmacogenomics fits in cardiology practice

ACS and PCI workflows stroke and AFib prevention lipid management and risk scores

Key ADME pathways for cardiology drugs

phase 1 and phase 2 metabolism hepatic vs renal clearance transporters and uptake

Risk outcomes: thrombosis, bleeding and myopathy overview

stent thrombosis and stroke major bleeding events CK elevation and rhabdomyolysis

Session 2

Fee: Rs 11800

Antiplatelets, Thrombosis Risk & PGx

Concepts around antiplatelet response variability

prodrugs vs active drugs on treatment platelet reactivity high on treatment platelet reactivity

Gene–drug concepts for antiplatelets (CYP metabolism)

reduced function vs normal activity effect on active metabolite formation thrombosis vs bleeding trade offs

Antiplatelet choice and dose themes in PGx guidelines

when to consider alternative agents balancing ischemic and bleeding risks multidisciplinary decision making

Session 3

Fee: Rs 14800

Statins, Myopathy Risk & PGx

Mechanisms of statin induced myopathy (conceptual)

exposure driven risk drug–drug interactions patient susceptibility factors

Transporter related concepts for statin uptake and exposure

hepatic uptake transporters higher systemic concentrations myopathy signal recognition

Statin selection, dosing and follow up themes in PGx

starting and target doses panel vs single gene considerations CK monitoring and symptom review

Session 4

Fee: Rs 18800

Warfarin, Anticoagulation & PGx Caseboard

Warfarin dosing variability and PGx concepts

sensitivity vs resistance themes maintenance dose prediction intuition INR trajectories and safety

Clinical factors plus PGx in anticoagulation decisions

age, comorbidities, interactions bridging and overlap periods role of DOAC options

Mini capstone: cardiology PGx clinic note and board slide

summarize antiplatelet, statin and anticoagulant PGx clear risk and action bullets ready for cardiology case discussions

PDF

PGx in Cardiology — Antiplatelets, Statins & Warfarin Training | Gene–Drug Pairs & Dose Individualization

PGx in Cardiology — Antiplatelets, Statins & Warfarin — Hands-on